Abbott Laboratories (ABT) Price History:-33.81%(TTM)
The price cagr for Abbott Laboratories (ABT) is -33.81% over the latest trailing 12-month period. The comparable SPY value is +20.75%. Year-to-date price return is -28.49%. Price CAGR uses adjusted close price history and excludes dividends.
Current Price
$88.81
$-2.44 (-2.67%)
Previous Close: $91.25
Today's Trading
- Open
- $91.31
- Day High
- $91.32
- Day Low
- $88.72
- Volume
- 7.73M
- Avg Volume
- 11.76M
52-Week Position
12%
of the 52-week price range
- From 52-week high
- -36.14%
- From 52-week low
- +8.34%
52-Week Price Range
52-Week Low
$81.97
May 11, 2026
Current Price
$88.81
12% of range
52-Week High
$139.06
Jun 24, 2025
Price Returns by Period
1 Day
-2.67%
7 Days
+2.09%
30 Days
+7.57%
YTD
-28.49%
1 Year
-33.79%
vs 52W High
-36.14%
ABT Price Chart
Long-Term Performance (CAGR)
Price CAGR (3Y)
-4.41%
Price CAGR (5Y)
-4.22%
Total Return CAGR (3Y)
-2.46%
Total Return CAGR (5Y)
-2.39%
CAGR (Compound Annual Growth Rate) shows the annualized return over the specified period. Total Return includes dividends reinvested.
Key Price Statistics
| Current Price | $88.81 |
| Previous Close | $91.25 |
| Day Range | $88.72 - $91.32 |
| 52-Week Range | $81.97 - $139.06 |
| Volume | 7.73M |
| Average Volume | 11.76M |
| Market Cap | $154.66B |
| % from 52W High | -36.14% |
Related Metrics
About Abbott Laboratories
Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular ailments. It also supplies diabetes care products and neuromodulation devices designed for the management of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories maintains its corporate headquarters in North Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Robert Ford